Case Study: Exploring A Digital Innovation in Prostate Cancer Care
We’re pleased to share a new case study led by Health Innovation Oxford & Thames Valley, in partnership with Bayer Plc, exploring how the Wave Health digital health solution supports core NHS priorities including data-driven, scalable care. 🏥
Wave Health is an MHRA-registered Software as a Medical Device (SaMD) designed to turn patient-reported data into actionable insights through remote monitoring, proactive risk management and patient supported self-management.
Since the prostate cancer study, Wave Health has focused on real-world adoption including regulatory compliance, NHS workflow integration options, and deployment readiness across multiple care pathways.
Next step: moving into live clinical environments to generate local evidence and support sustainable adoption. We look forward to collaborating with partners to take this into NHS settings.
🔗 Read the full case study here: https://lnkd.in/en56pwzw
Declarations of Interests and Roles
Wave Health is manufactured by Treatment Technologies & Insights (TTI). Health Innovation Oxford & Thames Valley was sponsored by Bayer Plc to conduct an independent feasibility study on the TTI technology. Bayer Plc partners with TTI solely as the UK marketing agent for the prostate cancer version of Wave Health and is not responsible for the product’s content or functionality.
This product is owned by TTI. Bayer and TTI have an arrangement under which Bayer has partially funded UK market development work, and Bayer markets the product in the UK on TTI's behalf. This is a standalone product and is not connected with any medicinal products.